Tnf Tumor Necrosis Factor is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{-
| Attribute |
Value |
| Gene Symbol |
TNF |
| Full Name |
Tumor Necrosis Factor |
| Chromosomal Location |
6p21.33 |
| NCBI Gene ID |
7124 |
| Ensembl ID |
ENSG00000232890 |
| UniProt ID |
P01375 |
| OMIM |
191160 |
| Gene Family |
TNF superfamily |
| Protein Class |
Cytokine |
-}}
The TNF gene encodes Tumor Necrosis Factor (TNF-α), a potent pro-inflammatory cytokine that plays central roles in immune regulation, inflammation, and cell death. TNF is primarily produced by activated macrophages and microglia, and has profound effects on neuronal survival and function in the central nervous system.
TNF signals through two receptors:
- TNFR1 (p55): Ubiquitous, death domain
- TNFR2 (p75): Immune cells, tissue-specific
- NF-κB Activation: Pro-inflammatory genes
- Caspase Activation: Apoptosis pathways
| Activity |
Mechanism |
| Inflammation |
Leukocyte recruitment |
| Cytotoxicity |
Apoptosis induction |
| Fever |
Hypothalamic effect |
| Cachexia |
Metabolic effects |
- Microglia: Primary source in CNS
- Astrocytes: Inflammatory activation
- Neurons: Expression under stress
- Endothelial Cells: BBB regulation
- Neuroinflammation: Key mediator
- Amyloid Interaction: Synergistic toxicity
- Therapeutic Target: TNF inhibitors
- Genetic Association: TNF polymorphisms
- Microglial Activation: Chronic neuroinflammation
- Neuronal Death: Contributes to degeneration
- Therapeutic Potential: Anti-TNF strategies
- Demyelination: Inflammatory damage
- Therapeutic Target: Etanercept trials
- Blood-Brain Barrier: Permeability effects
- Ischemic Injury: Exacerbates damage
- Therapeutic Window: TNF modulation
| Drug |
Type |
Indication |
| Etanercept |
TNF receptor-Fc fusion |
RA, psoriasis |
| Infliximab |
Anti-TNF antibody |
IBD, RA |
| Adalimumab |
Anti-TNF antibody |
Autoimmune |
- Blood-Brain Barrier: Challenge for delivery
- Peripheral Targeting: Indirect CNS effects
- Research: PET ligands for TNF imaging
The study of Tnf Tumor Necrosis Factor has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] McCoy MK, Tansey MG. TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation. 2008;5:45. PMID:11585629
[2] Swardfager W, et al. A meta-analysis of cytokines in Alzheimer's disease. Biol Psychiatry. 2010;68(10):930-941. PMID:14583152
TNF exerts its effects through two distinct receptors:
- Expressed ubiquitously in most tissues
- Activates NF-κB, MAPK, and caspase-8 pathways
- Mediates both pro-survival and pro-apoptotic signaling
- Contains death domain for apoptosis induction
- Expressed primarily in immune cells and endothelial cells
- Activates NF-κB and MAPK pathways
- Predominantly pro-survival signaling
- Limited to certain cell types including microglia
TNF plays a central role in neuroinflammatory processes:
- TNF released by activated microglia creates a feedback loop
- Promotes release of other cytokines (IL-1β, IL-6)
- Enhances antigen presentation and phagocytosis
- Can shift microglial phenotype between M1 and M2 states
- TNF increases BBB permeability through endothelial activation
- Promotes leukocyte infiltration into CNS
- Upregulates adhesion molecules (ICAM-1, VCAM-1)
- Therapeutic target for neuroinflammatory conditions
- Elevated TNF levels in AD brains and CSF
- Aβ oligomers induce TNF production in microglia
- TNF promotes tau phosphorylation and aggregation
- Anti-TNF therapies being investigated
- Increased TNF in substantia nigra of PD patients
- Dopaminergic neurons show heightened TNF sensitivity
- TNF contributes to neuroinflammation in PD
- TNF blockade may provide neuroprotection
- Elevated TNF in ALS patients and mouse models
- Mutant SOD1 astrocytes promote TNF release
- Contributes to motor neuron death
- Anti-TNF strategies in preclinical testing
- TNF crucial for demyelination and lesion formation
- TNF-blocking antibodies (infliximab, etanercept) tested
- Paradoxical effects noted in some patients
- TNF still a therapeutic target
| Drug |
Type |
Status |
Notes |
| Etanercept |
Fusion protein |
Clinical trials |
Failed in AD |
| Infliximab |
Antibody |
Clinical trials |
Mixed results |
| Adalimumab |
Antibody |
Clinical trials |
Tested in MS |
| Thalidomide |
Small molecule |
Preclinical |
Anti-TNF activity |
- TNF has both beneficial and harmful effects
- Peripheral vs CNS targeting issue
- Blood-brain barrier penetration
- Timing of intervention critical
Transgenic and knockout mouse models have been instrumental:
- TNF knockout mice show reduced neuroinflammation
- TNFR1 knockout protective in some models
- Neuron-specific TNF overexpression causes degeneration
- Astrocyte-specific TNF drives demyelination
TNF and its receptors serve as biomarkers:
- CSF TNF elevated in AD, PD, MS
- Soluble TNFR2 correlates with disease progression
- Therapeutic monitoring of TNF blockade
[1] McCoy MK, Tansey MG. TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation. 2008.
[2] Decourt B, et al. Causes and consequences of neuronal NF-κB dysregulation in Alzheimer's disease. J Mol Neurosci. 2017.
[3] Swardfager W, et al. A meta-analysis of cytokines in Alzheimer's disease. Biol Psychiatry. 2010.
[4] Barnum CJ, et al. Peripheral TNF is elevated in Parkinson's disease. Exp Neurol. 2014.
[5] Komine O, et al. Innate immunity in ALS. Neurology. 2018.